(Q37315399)

19 August 2017

1 reference

title

Potential role of mesenchymal stromal cells in pediatric hematopoietic SCT. (English)

1 reference

19 August 2017

L M Ball

1

1 reference

19 August 2017

M E Bernardo

series ordinal

2

1 reference

19 August 2017

F Locatelli

series ordinal

3

1 reference

19 August 2017

R M Egeler

series ordinal

4

1 reference

19 August 2017

language of work or name

English

0 references

publication date

1 October 2008

1 reference

Bone Marrow Transplantation

19 August 2017

1 reference

19 August 2017

42 Suppl 2

1 reference

19 August 2017

S60-6

1 reference

https://scigraph.springernature.com/pub.10.1038/bmt.2008.286

19 August 2017

0 references

cites work

Hematopoietic reconstitution in a patient with Fanconi's anemia by means of umbilical-cord blood from an HLA-identical sibling

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.286

Marrow stromal cells as stem cells for nonhematopoietic tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.286

7 January 2021

Phenotypic and functional comparison of cultures of marrow-derived mesenchymal stem cells (MSCs) and stromal cells.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.286

7 January 2021

Cotransplantation of stroma results in enhancement of engraftment and early expression of donor hematopoietic stem cells in utero

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.286

7 January 2021

Nonexpanded primary lung and bone marrow–derived mesenchymal cells promote the engraftment of umbilical cord blood–derived CD34+ cells in NOD/SCID mice

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.286

7 January 2021

Clarification of the nomenclature for MSC: The International Society for Cellular Therapy position statement.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.286

7 January 2021

In vitro differentiation of bone and hypertrophic cartilage from periosteal-derived cells

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.286

7 January 2021

Identification of mesenchymal stem/progenitor cells in human first-trimester fetal blood, liver, and bone marrow.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.286

7 January 2021

Detection of stromal cells in peripheral blood progenitor cell collections from breast cancer patients

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.286

7 January 2021

Mesenchymal progenitor cells in human umbilical cord blood

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.286

7 January 2021

Amniotic fluid as a novel source of mesenchymal stem cells for therapeutic transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.286

7 January 2021

Prospective isolation and characterization of mesenchymal stem cells from human placenta using a frizzled-9-specific monoclonal antibody.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.286

7 January 2021

Replicative aging and gene expression in long-term cultures of human bone marrow stromal cells.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.286

7 January 2021

Platelet-rich plasma improves expansion of human mesenchymal stem cells and retains differentiation capacity and in vivo bone formation in calcium phosphate ceramics.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.286

7 January 2021

Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.286

7 January 2021

Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.286

7 January 2021

Human mesenchymal stem cells modulate allogeneic immune cell responses

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.286

7 January 2021

Interactions between human mesenchymal stem cells and natural killer cells

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.286

7 January 2021

Donor-derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a nonmyeloablative setting

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.286

7 January 2021

Immunomodulatory properties of mesenchymal stromal cells

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.286

7 January 2021

Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.286

7 January 2021

Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.286

7 January 2021

Mesenchymal stem cells are capable of homing to the bone marrow of non-human primates following systemic infusion.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.286

7 January 2021

Mesenchymal stem cells promote engraftment of human umbilical cord blood-derived CD34(+) cells in NOD/SCID mice

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.286

7 January 2021

Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.286

7 January 2021

Adipose tissue-derived mesenchymal stem cells have in vivo immunosuppressive properties applicable for the control of the graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.286

7 January 2021

Human bone marrow stromal cell treatment improves neurological functional recovery in EAE mice

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.286

7 January 2021

Reversal of the immunosuppressive properties of mesenchymal stem cells by tumor necrosis factor alpha in collagen-induced arthritis.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.286

7 January 2021

Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.286

7 January 2021

Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.286

7 January 2021

Bone marrow-derived mesenchymal stem cells remain host-derived despite successful hematopoietic engraftment after allogeneic transplantation in patients with lysosomal and peroxisomal storage diseases

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.286

7 January 2021

Allogeneic mesenchymal stem cell infusion for treatment of metachromatic leukodystrophy (MLD) and Hurler syndrome (MPS-IH).

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.286

7 January 2021

Clinical responses to bone marrow transplantation in children with severe osteogenesis imperfecta

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.286

7 January 2021

Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: Implications for cell therapy of bone

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.286

7 January 2021

Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.286

7 January 2021

Megadose transplantation of purified peripheral blood CD34(+) progenitor cells from HLA-mismatched parental donors in children

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.286

7 January 2021

Increased stem cell dose, as obtained using currently available technology, may not be sufficient for engraftment of haploidentical stem cell transplants

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.286

7 January 2021

Cotransplantation of ex vivo expanded mesenchymal stem cells accelerates lymphocyte recovery and may reduce the risk of graft failure in haploidentical hematopoietic stem-cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.286

7 January 2021

Umbilical cord blood transplantation: current state of the art.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.286

7 January 2021

Searching for unrelated donor hematopoietic stem cells: availability and speed of umbilical cord blood versus bone marrow

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.286

7 January 2021

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.286

7 January 2021

Graft-versus-host disease in children who have received a cord-blood or bone marrow transplant from an HLA-identical sibling. Eurocord and International Bone Marrow Transplant Registry Working Committee on Alternative Donor and Stem Cell Sources.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.286

7 January 2021

Comparison of outcomes of unrelated bone marrow and umbilical cord blood transplants in children with acute leukemia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.286

7 January 2021

Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.286

7 January 2021

EBMT 2006, Hamburg, Germany, March 19-22, 2006. Abstracts

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.286

7 January 2021

Acute graft-versus-host disease: pathophysiology, clinical manifestations, and management.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.286

7 January 2021

How I treat refractory acute GVHD.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.286

7 January 2021

Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.286

7 January 2021

A new cell therapy registry coordinated by the European Group for Blood and Marrow Transplantation (EBMT)

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.286

7 January 2021

Mesenchymal stem cells exert differential effects on alloantigen and virus-specific T-cell responses

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.286

7 January 2021

Tissue repair using allogeneic mesenchymal stem cells for hemorrhagic cystitis, pneumomediastinum and perforated colon

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.286

7 January 2021

Identifiers

DOI

10.1038/BMT.2008.286

1 reference

19 August 2017

1 reference